title: Sleep disturbances associated with gastro-oesophageal reflux disease: prevalence and impact of treatment in French primary care patients.
abstract: OBJECTIVE
  To evaluate the prevalence of sleep disturbances in French patients with gastro-oesophageal reflux disease and the impact of gastro-oesophageal reflux disease treatment on sleep.
  
  
  METHODS
  A registry was compiled of all gastro-oesophageal reflux disease patients seen during a 2-week period by 1983 French primary care physicians. Data from the first two patients with nocturnal gastro-oesophageal reflux disease symptoms and gastro-oesophageal reflux disease-related sleep disturbances seen by each physician were derived from physician questionnaires and medical records. These patients completed a questionnaire during the initial consultation and after 1-month treatment.
  
  
  RESULTS
  A total of 33,391 patients were included in the study: physician questionnaires were available for 3269 patients and patient questionnaires for 2876. Nocturnal gastro-oesophageal reflux disease symptoms were reported by 21,337 patients (63.9%) and regular (at least once weekly) gastro-oesophageal reflux disease-related sleep disturbances by 19,313 (61.7%). Multivariate analysis showed that nocturnal gastro-oesophageal reflux disease symptoms, use of hypnotic drugs, and age over 50 years were significant independent predictors of sleep disturbances. The proportion of patients reporting at least one nocturnal gastro-oesophageal reflux disease symptom during the previous week decreased following treatment, from 98.8% to 39.3% (P<0.001).
  
  
  CONCLUSIONS
  Nocturnal gastro-oesophageal reflux disease symptoms are common in the French population and are associated with sleep disturbances. Effective treatment can significantly improve sleep duration and quality.
authors.affiliation: Service d'Hépato-Gastro-entérologie, CHU Robert Debré, Rue du Général Koenig, Reims Cedex, France. gcadiot@chu-reims.fr
authors.forename: Guillaume
authors.initials: G
authors.lastname: Cadiot
authors.forename: Pierre-Henri
authors.initials: PH
authors.lastname: Delaage
authors.forename: Caroline
authors.initials: C
authors.lastname: Fabry
authors.forename: Christine
authors.initials: C
authors.lastname: Soufflet
authors.forename: Philippe
authors.initials: P
authors.lastname: Barthélemy
mesh_terms: D000328:Adult; D000367:Age Factors; D000464:Alginates / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D005260:Female; D005602:France / Q000453:epidemiology; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000188:drug therapy*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D011320:Primary Health Care / Q000706:statistics & numerical data; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000150:complications* / Q000453:epidemiology*; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000464:Alginates; D000863:Antacids; D006635:Histamine H2 Antagonists; D006993:Hypnotics and Sedatives; D054328:Proton Pump Inhibitors